Mesar Plus

Olmesartan medoxomil and hydrochlorothiazide, the active ingredients in Mesar Plus, are an Angiotensin II receptor blocker (ARB) and a thiazide diuretic presented as an oral tablet for oral use. They work together to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Mesar Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is manufactured under GMP conditions. It is distributed through a validated logistics network to ensure product integrity during global shipment.

Mesar Plus, a combination of an ARB and a thiazide diuretic, is indicated for the management of hypertension.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Secondary hypertension: assists in blood pressure control when hypertension is due to renal or endocrine causes.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Increased frequency of urination due to the diuretic effect. - Mild headache or fatigue.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema). - Significant electrolyte disturbances such as hyponatremia or hypokalemia. - Acute kidney injury or worsening renal function. - Persistent low blood pressure (hypotension) leading to fainting. - Pancreatitis or severe liver injury (very rare).

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to ensure adequate control. - Assess renal function and serum electrolytes, especially potassium and sodium levels. - Adjust dose or discontinue if significant dehydration or electrolyte imbalance occurs. - Use with caution in patients with severe hepatic impairment. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mesar Plus may interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Lithium: risk of lithium toxicity due to reduced renal clearance. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - ACE inhibitors or aliskiren in diabetic patients: increased risk of renal impairment. - NSAIDs (high‑dose or chronic use): may blunt antihypertensive effect and affect kidney function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering. - Diuretics other than thiazides: monitor electrolytes and volume status. - Antidiabetic agents: blood glucose may improve, requiring dose adjustment. - Digoxin: increased risk of digoxin toxicity in the setting of electrolyte disturbances.